Phase 3 Study of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Late-stage Non-squamous Non-small-cell Lung Cancer

NCT01999673 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

582

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small-Cell Lung Cancer Stage IIIB
Non-Small-Cell Lung Cancer Stage IV
Non-Small-Cell Lung Cancer Metastatic
Carcinoma, Non-Small-Cell Lung
Non-Small Cell Lung Cancer
Non-Small-Cell Lung Carcinoma
Nonsmall Cell Lung Cancer

Interventions

BIOLOGICAL: bavituximab
DRUG: Docetaxel
OTHER: Placebo (for bavituximab)

Sponsor

Peregrine Pharmaceuticals